Abstract: The present invention relates to a process for the preparation of a europium-doped alkaline-earth metal siliconitride or silicooxynitride having increased emission efficiency. The present invention furthermore relates to europium-doped alkaline-earth metal siliconitrides or silicooxynitrides which are obtainable by the preparation process according to the invention, and to the use of the europium-doped alkaline-earth metal siliconitrides or silicooxynitrides according to the invention as conversion phosphors. The present invention furthermore also relates to a light-emitting device which comprises a europium-doped alkaline-earth metal siliconitride or silicooxynitride according to the invention.

Abstract: The invention relates to bimesogenic compounds of formula I wherein R11, R12, MG11, MG12, X11, X12 and Sp1 have the meaning given in claim 1, to the use of bimesogenic compounds of formula I in liquid crystal media and particular to flexoelectric liquid crystal devices comprising a liquid crystal medium according to the present invention.

Abstract: The invention relates to novel polymers of benzodithiophene, methods and materials for their preparation, their use as semiconductors in organic electronic (OE) devices, and to OE devices comprising these polymers.

Abstract: The present invention relates to a liquid crystal (LC) display of the FFS type comprising a liquid crystal medium with negative dielectric anisotropy and a di- or multireactive polymerizable compound, and an alignment layer inducing planar alignment in the LC medium.

Abstract: The invention relates to bimesogenic compounds of formula I wherein R11, R12, MG11, MG12, X11, X12 and Sp1 have the meaning given in claim 1, to the use of bimesogenic compounds of formula I in liquid crystal media and particular to flexoelectric liquid crystal devices comprising a liquid crystal medium according to the present invention.

Abstract: The present invention relates to certain fluorenes, to the use of the compounds in an electronic device, and to an electronic device comprising at least one of these compounds. The present invention furthermore relates to a process for the preparation of the compounds and to a formulation and composition comprising one or more of the compounds.

Abstract: The invention relates to liquid-crystalline media which can be used, in particular, for electro-optical displays having active-matrix addressing based on the ECB effect and for IPS (in-plane switching) displays or FFS (fringe field switching) displays.

Abstract: The present invention relates to metal complexes of the general formulae I to V, in particular as emitter molecules in organic electronic devices, to ligands of the general formulae Ia to Va, and to the use thereof for the preparation of metal complexes, to a layer and an electronic device which comprise the compounds according to the invention, and to a process for the preparation of the compounds according to the invention.

Abstract: The present invention relates to ?-polylysine conjugates, in particular conjugates of ?-polylysine with compounds carrying carboxyl groups, and to the preparation and use thereof for targeting of the kidney.

Abstract: The present invention relates to a fluorine-bridged associate consisting of an oligomer or polymer containing fluorine radicals which are bonded to the oligomer or polymer backbone, and up to three types of functional units in the backbone which differ with respect to function and are selected from the group consisting of a hole-transport and/or hole-injection unit, an electron-transport and/or electron-injection unit and an emitter unit, and one to three types of compounds containing a fluorine radical which differ with respect to function and are selected from a hole-transport and/or hole-injection unit, an electron-transport and/or electron-injection unit and an emitter unit, and to an opto-electronic device in which the fluorine-bridged associate is employed.

Abstract: The invention describes electronic devices comprising a metal complex compound having at least one ligand containing an N donor and a P donor having the formula (I), in which the carbons C1 and C2 are part of an aromatic or non-aromatic ring system F1, P and N are phosphorus and nitrogen, where the nitrogen is in sp2-hybridized form, the radicals R3 and R4 are, independently of one another, hydrogen or an alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, alkylcycloalkyl, heteroalkyl, heterocycloalkyl, heteroalkylcycloalkyl, aryl, heteroaryl, aralkyl or heteroaralkyl radical having up to 40 C atoms, and R1 and R2 are, independently of one another, an atom or radical from the group comprising hydrogen, halogen, R, RO—, RS—, RCO—, RCOO—, RNH—, R2N—, RCONR— and —Si(R)X(OR)3-X, where R=an alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, alkylcycloalkyl, heteroalkyl, heterocycloalkyl, heteroalkylcycloalkyl, aryl, heteroaryl, aralkyl or heteroaralkyl radical having up to 40 C atoms and

Abstract: Compounds of the formula (I), in which R1, R2, R2a and R3 have the meanings indicated in Claim 1, are inhibitors of PDK1 and cell proliferation/cell vitality and can be employed for the treatment of tumors.

Abstract: The invention relates to compounds of the general formula (I): Lu3?x?zAxAl5?y?zScyO12:MnzCaz,, where A stands for Y, Gd or Tb, x stands for a value from the range from 0 to 2.90, y stands for a value from the range from 0 to 0.50, z stands for a value from the range from 0.005 to 0.05, and to a process for the preparation of these phosphors and to the use thereof as conversion phosphors or in lamps.

Abstract: Compounds of the formula I in which A, L1, L2, X and Y have the meanings indicated in Claim 1, are inhibitors of Syk, and can be employed, inter alia, for the treatment of rheumatoid arthritis.

Abstract: The invention relates to a method for stabilizing solid pharmaceutical administration forms which comprises at least one species of microorganism, and to a pack comprising packaging and a solid pharmaceutical administration form which comprises at least one species of microorganism.

Abstract: The present invention provides novel pyrimidine and pyridine compounds according to Formula (I), Formula (II), Formula (III), Formula (IV) and Formula (V) their manufacture and use for the treatment of hyperproliferative diseases including, but not limited to, cancer, lupus, allergic disorders, Sjogren's disease and rheumatoid arthritis. In preferred embodiments, the present invention describes irreversible kinase inhibitors including, but not limited to, inhibitors of Bruton's tyrosine kinase.

Abstract: The present invention relates to an electronic device, in particular an organic electroluminescent device, which comprises metal complexes containing azaborole ligands. The invention also relates to the metal complexes themselves, to the use thereof in an organic electronic device, and to a process for the preparation thereof. Finally, the invention is directed to the ligands and to the use of the ligands for the preparation of the metal complexes according to the invention.

Abstract: The present invention relates to a method for producing solar cells with local back surface field (LBSF) using an alkaline etching paste which allows the back surface to be polished and the back surface edges to be insulated in a single process step.

Abstract: The present invention provides fused bicyclic triazole derivatives of Formula (I) useful as gamma secretase modulators (GSM), for the treatment of Alzheimer's disease and related diseases.

Abstract: The present invention relates to the use of phenyl ketone derivatives of the formula I for use as self-tanning substance or for increasing melanin synthesis, improving melanin transport and/or improving the distribution of melanin in suprabasal layers, and to preparations comprising these phenyl ketone derivatives.